Department of Hepatic Surgery, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zhongshan People's Hospital Affiliated to Guangdong Medical University, Guangdong, China.
Eur J Surg Oncol. 2022 Sep;48(9):2014-2022. doi: 10.1016/j.ejso.2022.05.006. Epub 2022 May 13.
Ruptured hepatocellular carcinoma (rHCC) generally has a very poor prognosis and is currently classified as T4 in the tumor-node-metastasis (TNM) staging system. In this study, we aimed to demonstrate the actual impact of rHCC, as well as the positive effect of hepatectomy in patients with Barcelona Clinic Liver Cancer (BCLC) stage 0/A rHCC.
We enrolled 86 patients with rHCC after surgery and 526 patients with non-rHCC after surgery or transcatheter arterial chemoembolization (TACE). Survival curves were plotted using the Kaplan-Meier method to compare the postoperative prognosis of patients with rHCC with that of patients with non-rHCC. Univariate and multivariate Cox regression analyses were used to identify the risk factors affecting patient survival.
BCLC stage 0/A rHCC treated with surgery had a worse prognosis than BCLC stage 0/A non-rHCC treated with surgery (overall survival [OS]: hazard ratio [HR] = 3.12 [2.24-4.34], P < 0.001; recurrence-free survival [RFS]: HR = 2.26 [1.65-3.09], P < 0.001). Rupture was an independent prognostic factor in patients with BCLC stage 0/A rHCC (OS: HR = 1.685 [1.416-2.006], P < 0.001; RFS: HR = 1.484 [1.267-1.737], P < 0.001), and patients with BCLC stage 0/A rHCC who underwent surgery had a comparable prognosis to patients with BCLC stage B HCC who underwent surgery or TACE (OS: P = 0.78).
Patients classified as having BCLC stage 0/A rHCC can achieve comparable outcomes to patients with BCLC stage B HCC after hepatectomy. However, not all patients with rHCC should be classified as T4 in the TNM staging system.
破裂型肝细胞癌(rHCC)通常预后极差,目前在肿瘤-淋巴结-转移(TNM)分期系统中被归类为 T4。本研究旨在证明 rHCC 的实际影响,以及巴塞罗那临床肝癌(BCLC)分期 0/A rHCC 患者行肝切除术的积极作用。
我们纳入了 86 例 rHCC 术后患者和 526 例非 rHCC 术后或经导管动脉化疗栓塞(TACE)患者。采用 Kaplan-Meier 法绘制生存曲线,比较 rHCC 术后患者与非 rHCC 术后患者的预后。采用单因素和多因素 Cox 回归分析确定影响患者生存的危险因素。
BCLC 分期 0/A rHCC 患者行手术治疗的预后较 BCLC 分期 0/A 非 rHCC 患者行手术治疗的预后更差(总生存[OS]:风险比[HR] = 3.12[2.24-4.34],P < 0.001;无复发生存[RFS]:HR = 2.26[1.65-3.09],P < 0.001)。破裂是 BCLC 分期 0/A rHCC 患者的独立预后因素(OS:HR = 1.685[1.416-2.006],P < 0.001;RFS:HR = 1.484[1.267-1.737],P < 0.001),且行手术治疗的 BCLC 分期 0/A rHCC 患者的预后与行手术或 TACE 治疗的 BCLC 分期 B HCC 患者的预后相当(OS:P = 0.78)。
BCLC 分期 0/A rHCC 患者行肝切除术可获得与 BCLC 分期 B HCC 患者相当的疗效。然而,并非所有 rHCC 患者都应被归类为 TNM 分期系统中的 T4。